For Pharmaceutical Manufacturers
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30 Under the 2026 CMS Final Rule, pharmaceutical manufacturers face a new compliance requirement: beginning with Q1 2026 ASP reporting, manufacturers must submit a Reasonable Assumptions Form...
PBM Reform Is Here: What the 2026 Appropriations Act Changes
Congress Just Drew a Line on PBM Compensation Recently, President Trump signed the Consolidated Appropriations Act of 2026, avoiding a government shutdown and setting federal funding for the year. Included inside the bill is a major policy change that will reshape how...
Nevada Essential Drug List Reporting Requirements for Pharmaceutical Manufacturers
Nevada Essential Drug List Reporting Requirements for Pharmaceutical Manufacturers Nevada’s drug price transparency law includes annual reporting obligations for pharmaceutical manufacturers whose products appear on the Nevada Essential Drug List. Inclusion on the...
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30
CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30 Under the 2026 CMS Final Rule, pharmaceutical manufacturers face a new compliance requirement: beginning with Q1 2026 ASP reporting, manufacturers must submit a Reasonable Assumptions Form...
PBM Reform Is Here: What the 2026 Appropriations Act Changes
Congress Just Drew a Line on PBM Compensation Recently, President Trump signed the Consolidated Appropriations Act of 2026, avoiding a government shutdown and setting federal funding for the year. Included inside the bill is a major policy change that will reshape how...
Nevada Essential Drug List Reporting Requirements for Pharmaceutical Manufacturers
Nevada Essential Drug List Reporting Requirements for Pharmaceutical Manufacturers Nevada’s drug price transparency law includes annual reporting obligations for pharmaceutical manufacturers whose products appear on the Nevada Essential Drug List. Inclusion on the...
Baseline AMP: Guide to Compliance & Profitability
For pharmaceutical manufacturers, a comprehensive understanding of the Baseline Average Manufacturer Price (AMP) is crucial. Its establishment and calculation significantly impact profitability, compliance and long-term value of your product. In this white paper,...
Navigating Texas Medicaid Formulary: Guide for Pharma Mfrs
NAVIGATING THE TEXAS MEDICAID FORMULARY: A Comprehensive Guide for Pharmaceutical ManufacturersThe landscape of pharmaceutical product listing in Texas presents unique challenges for manufacturers seeking Medicaid coverage. Unlike other states, Texas operates its own...
Chargeback Processing: Best Practices to Avoid Revenue Loss
Chargeback Processing — Best Practices to Avoid Revenue Leakage & RiskChargeback processing, validation, and reconciliation are integral in maintaining a profitable business in the highly competitive U.S. pharmaceutical market. Profit margins are tight, especially...
Professor Jeremy’s
KEY TERMS
FOR PHARMA EXECUTIVES
Pharmaceutical professionals often face challenges with the industry’s language, acronyms, and key players. This glossary offers an overview of essential terms every executive should know.